Jim Cramer Calls Incyte “Way Too Cheap”

Group 1 - Incyte Corporation is highlighted as a relatively cheap stock within the S&P 500, particularly in the healthcare sector, which has struggled this year [1] - The company has nine approved products primarily in oncology and dermatology, along with a strong pipeline, contributing to a year-to-date stock increase of nearly 23% [1] - Incyte is projected to experience 19% earnings growth and trades at just under 12 times next year's earnings, indicating it is undervalued [1] Group 2 - The new CEO of Incyte, Bill Meury, is recognized as an industry veteran and deal maker, previously leading Karuna Therapeutics and holding a significant role at Allergan [2] - The potential of Incyte as an investment is acknowledged, although there are suggestions that certain AI stocks may offer better upside potential with less risk [2]